{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"3.2","value":"1.1"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"1.0","value":"1.0"},{"groupId":"OG002","lowerLimit":"0.5","upperLimit":"1.0","value":"0.8"},{"groupId":"OG003","lowerLimit":"0.9","upperLimit":"1.0","value":"1.0"},{"comment":"Median and upper limit of confidence interval (CI) were not estimable due to insufficient number of events.","groupId":"OG004","lowerLimit":"2.0","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"PFS: Interval from first study drug dose date to the earlier of first documentation of definitive progressive disease (PD) per IMWG Consensus Panel 1 Criteria or death from any cause. PD: an increase of 25% from the lowest response value in 1 of the following: Serum and urine M-protein (absolute increase ≥ 0.5 g/dL and ≥ 200 mg/24 hours, respectively); In participants without measurable serum and urine M-protein levels, the difference between involved and uninvolved FLC levels (absolute increase \\> 10 mg/dL); In participants without measurable serum and urine M-protein and without measurable disease by FLC levels, bone marrow PC percentage (absolute percentage ≥ 10%). Definite development of new bone lesions or STP or definite increase in the size of existing bone lesions or STPs; Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that can be attributed solely to PC proliferative disorder. Analysis was done using Kaplan-Meier (KM) estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"OG000","title":"Dose Escalation: 3 x 10^7 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"OG001","title":"Dose Escalation: 1 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 3 x 10\\^8 autologous anti-BCMA CAR T cells on Day 0.","id":"OG002","title":"Dose Escalation: 3 x 10^8 KITE-585"},{"description":"Participants with RRMM, received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day IV infusion for 3 days followed by a single infusion of KITE-585 at a dose of 1 x 10\\^9 autologous anti-BCMA CAR T cells on Day 0.","id":"OG003","title":"Dose Escalation: 1 x 10^9 KITE-585"},{"description":"RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min \\[Grade 2 chronic kidney disease\\]) received conditioning chemotherapy consisting of cyclophosphamide 300 mg/m\\^2/day and fludarabine 24 mg/m\\^2/day IV infusion for 3 days followed by single infusion of KITE-585 at a tolerable dose of 3 x 10\\^7 autologous anti-BCMA CAR T cells on Day 0.","id":"OG004","title":"Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585"}],"paramType":"MEDIAN","populationDescription":"Participants in the Safety Analysis Set were analyzed. Participants not meeting the criteria for PD by the analysis data cutoff date were censored at their last evaluable disease assessment date before any other anti-cancer therapies including stem cell transplant.","reportingStatus":"POSTED","timeFrame":"From KITE-585 infusion to the earlier date of data cutoff and first administration of other anti-cancer therapies including stem cell transplant (maximum: 17.6 months)","title":"Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1","type":"SECONDARY","unitOfMeasure":"months"}